Simcere Pharmaceutical Group

Simcere Pharmaceutical Group says it was founded in 1995 and is an innovation- and R&D-driven pharmaceutical company headquartered in Nanjing. Its current therapeutic focus is neuroscience, oncology, autoimmune disease and anti-infection, and its operating model combines in-house research with strategic cooperation with innovative biotechnology companies and research institutes. The company’s milestone history also records the creation of a national key laboratory of translational medicine and innovative drugs and the establishment of Shanghai, Boston, Beijing and Hongqiao innovation or R&D centers. [1]

Simcere’s current product portfolio describes three Category I innovative pharmaceuticals and one imported innovative pharmaceutical developed and launched in China. The company says more than 10 products are recommended in over 50 clinical-practice guidelines or pathways and more than 45 products are included in China’s National Reimbursement Drug List. Its listed products include suvemcitug and trilaciclib in oncology, daridorexant and Sanbexin in neuroscience, iguratimod in autoimmune disease, and clulevibart and simnotrelvir/ritonavir in anti-infection. Product indications and regulatory status are product-specific, so the portfolio should not be read as a claim that every product is approved for every listed use. [2]

Simcere’s 2025 ESG report provides a current innovation measure: the group invested RMB2.076 billion in R&D, approximately 26.8 percent of revenue, managed more than 60 new-drug pipelines, added three externally licensed products and had two new-drug marketing applications accepted by China’s National Medical Products Administration. The report also describes open collaboration through a Simcere State Key Laboratory exploration project involving global experts in neurology and oncology. [3]